AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33401364 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative home monitoring system (remote patient monitoring, Telus Canada)
Number of subjects: 54
Study 33401365 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative home monitoring (POHM)
Number of subjects: 54
Study 33401365 — intervention group
Group type: COMPARATOR
Intervention: Historical standard of care (control)
Number of subjects: 54
Study 33401363 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Recovery Pathway (ERP) including patient education, psychological screening, multimodal pre-emptive analgesia, nausea prophylaxis, early Foley catheter removal, and respiratory exercises.
Number of subjects: 29
Study 33401367 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery Assessment by Phone Points (RAPP) app with SwQoR questionnaire
Number of subjects: 494
Study 33401367 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 494
Study 33401942 — intervention group
Group type: EXPERIMENTAL
Intervention: General practitioners' understanding of HFpEF
Number of subjects: 35
Study 33401942 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication of diagnosis
Number of subjects: 35
Study 33401942 — intervention group
Group type: EXPERIMENTAL
Intervention: Management of people with HFpEF
Number of subjects: 35
Study 33401942 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuity of care
Number of subjects: 35
Study 33401942 — intervention group
Group type: EXPERIMENTAL
Intervention: Learning needs for GPs
Number of subjects: 35
Study 33402222 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy of brown flaxseed (30 g milled) and hesperidin (two 500 mg capsules) during lifestyle intervention
Number of subjects: 48
Study 33402222 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy of brown flaxseed and hesperidin
Number of subjects: 48
Study 33402367 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 1 Diabetes (T1D)
Number of subjects: 0
Study 33402367 — intervention group
Group type: COMPARATOR
Intervention: Control youth with normal weight or obesity and youth with Type 2 Diabetes (T2D)
Number of subjects: 0
Study 33402692 — intervention group
Group type: EXPERIMENTAL
Intervention: SSTR2 targeting using PEN-221, a cytotoxic drug conjugate.
Number of subjects: 402
Study 33402692 — intervention group
Group type: EXPERIMENTAL
Intervention: SSTR2 expression in NPC patients.
Number of subjects: 402
Study 33402861 — intervention group
Group type: EXPERIMENTAL
Intervention: WeReha device (12-week physiotherapy program including balance exercises, upper and lower limb exercises with specific motor tasks using a biofeedback system and exergaming)
Number of subjects: 25
Study 33403007 — intervention group
Group type: EXPERIMENTAL
Intervention: nal-IRI 50 mg/m² with fluorouracil/leucovorin (5-FU/LV) and oxaliplatin, administered in three cycles before and three cycles after surgical resection
Number of subjects: 72
Study 33403207 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 weeks of 'standard care' exercises
Number of subjects: 23
Study 33403364 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal membrane oxygenation (ECMO) initiated within 30 minutes of collapse
Number of subjects: 6
Study 33403367 — intervention group
Group type: EXPERIMENTAL
Intervention: NEWS2
Number of subjects: 175
Study 33403367 — intervention group
Group type: EXPERIMENTAL
Intervention: CURB-65
Number of subjects: 175
Study 33403367 — intervention group
Group type: EXPERIMENTAL
Intervention: PSI
Number of subjects: 175
Study 33403367 — intervention group
Group type: EXPERIMENTAL
Intervention: SIRS
Number of subjects: 175
Study 33403367 — intervention group
Group type: EXPERIMENTAL
Intervention: qSOFA
Number of subjects: 175
Study 33403401 — intervention group
Group type: EXPERIMENTAL
Intervention: Drugs used to prevent CIPN (B vitamins, calcium and magnesium infusion)
Number of subjects: 210
Study 33403401 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic adjustment of neurotoxic anticancer drugs
Number of subjects: 210
Study 33403401 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological management of CIPN
Number of subjects: 210
Study 33403831 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineralocorticoid receptor antagonist (MRA) added to conventional anti-failure therapy
Number of subjects: 12
Study 33404200 — intervention group
Group type: EXPERIMENTAL
Intervention: iGlarLixi
Number of subjects: 0
Study 33404367 — intervention group
Group type: EXPERIMENTAL
Intervention: Contraceptive methods used by patients with comorbidities; specific methods not detailed.
Number of subjects: 0
Study 33404367 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified; details on control group not available.
Number of subjects: 0
Study 33404513 — intervention group
Group type: EXPERIMENTAL
Intervention: PACO app (web-based eHealth app) for 8 weeks
Number of subjects: 60
Study 33404513 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list condition (no intervention for 4 weeks)
Number of subjects: 60
Study 33404519 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/day entecavir
Number of subjects: 29
Study 33404519 — intervention group
Group type: COMPARATOR
Intervention: 1.0 mg/day entecavir
Number of subjects: 29
Study 33404681 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower MCRI (Metabolic Clearance Rate of Insulin)
Number of subjects: 570
Study 33404681 — intervention group
Group type: EXPERIMENTAL
Intervention: MCRI
Number of subjects: 570
Study 33404789 — intervention group
Group type: EXPERIMENTAL
Intervention: White matter lesion (WML) burden
Number of subjects: 660
Study 33404789 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional connectivity (FC) of the DMN
Number of subjects: 660
Study 33404789 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional networks
Number of subjects: 660
Study 33405090 — intervention group
Group type: EXPERIMENTAL
Intervention: Selumetinib (KOSELUGO™; ARRY-142886)
Number of subjects: 0
Study 33405269 — intervention group
Group type: EXPERIMENTAL
Intervention: gemcitabine, trastuzumab plus erlotinib
Number of subjects: 63
Study 33405950 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative EOI MRD levels
Number of subjects: 249
Study 33405950 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate EOI MRD levels
Number of subjects: 249
Study 33405950 — intervention group
Group type: EXPERIMENTAL
Intervention: High EOI MRD levels
Number of subjects: 249
Study 33405950 — intervention group
Group type: EXPERIMENTAL
Intervention: High EOI MRD with AML-like consolidation therapy
Number of subjects: 249
Study 33405951 — intervention group
Group type: EXPERIMENTAL
Intervention: Average-risk treatment group
Number of subjects: 330
Study 33405951 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk treatment group
Number of subjects: 330
Study 33405951 — intervention group
Group type: COMPARATOR
Intervention: Overall cohort
Number of subjects: 330
Study 33406266 — intervention group
Group type: EXPERIMENTAL
Intervention: Nap sleep in healthy young adults
Number of subjects: 3
Study 33406266 — intervention group
Group type: COMPARATOR
Intervention: Nap sleep in healthy older adults
Number of subjects: 3
Study 33406266 — intervention group
Group type: COMPARATOR
Intervention: Nap sleep in older patients with mild cognitive impairment
Number of subjects: 3
Study 33406276 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 33406328 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin (600 mg every 12 hours starting the day before transplantation until day 14 after transplantation) plus tacrolimus and sirolimus
Number of subjects: 36
Study 33406989 — intervention group
Group type: EXPERIMENTAL
Intervention: Social marketing initiative to promote balance and strength classes
Number of subjects: 0
Study 33406996 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 2579
Study 33407104 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle modifications including individual counseling for nutritional education and physical activity over a 2-month weight reduction program.
Number of subjects: 36
Study 33407184 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute Kidney Injury (AKI) identified based on changes in blood creatinine levels according to the Kidney Disease: Improving Global Outcomes criteria.
Number of subjects: 30194
Study 33407184 — intervention group
Group type: EXPERIMENTAL
Intervention: Older adults aged 75 years or older.
Number of subjects: 30194
Study 33407184 — intervention group
Group type: EXPERIMENTAL
Intervention: AKI risk in older adults.
Number of subjects: 30194
Study 33407184 — intervention group
Group type: EXPERIMENTAL
Intervention: AKI association with in-hospital mortality.
Number of subjects: 30194
Study 33407194 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month supervised multicomponent exercise intervention (aerobic, muscular resistance, flexibility and postural exercises)
Number of subjects: 64
Study 33407194 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month supervised multicomponent exercise intervention
Number of subjects: 64
Study 33407194 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control Group)
Number of subjects: 64
Study 33407214 — intervention group
Group type: EXPERIMENTAL
Intervention: Days from ovulation until onset of nausea or vomiting
Number of subjects: 256
Study 33407214 — intervention group
Group type: COMPARATOR
Intervention: Days from last menstrual period (LMP) until onset of nausea or vomiting
Number of subjects: 256
Study 33407214 — intervention group
Group type: EXPERIMENTAL
Intervention: Human Chorionic Gonadotrophin rise
Number of subjects: 256
Study 33407224 — intervention group
Group type: EXPERIMENTAL
Intervention: ravulizumab
Number of subjects: 8
Study 33407305 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support
Number of subjects: 740
Study 33407305 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional coping
Number of subjects: 740
Study 33407305 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping self-efficacy
Number of subjects: 740
Study 33407305 — intervention group
Group type: EXPERIMENTAL
Intervention: Autonomous motivation
Number of subjects: 740
Study 33407440 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy treatment
Number of subjects: 148
Study 33407577 — intervention group
Group type: EXPERIMENTAL
Intervention: vemurafenib + PEG-IFN-α-2b
Number of subjects: 8
Study 33407577 — intervention group
Group type: EXPERIMENTAL
Intervention: vemurafenib + cobimetinib + PEG-IFN-α-2b
Number of subjects: 8
Study 33407671 — intervention group
Group type: EXPERIMENTAL
Intervention: PDHS-specific leukocyte genes
Number of subjects: 0
Study 33407671 — intervention group
Group type: EXPERIMENTAL
Intervention: PQDS-specific genes in leukocytes
Number of subjects: 0
Study 33407671 — intervention group
Group type: EXPERIMENTAL
Intervention: hsa-miR-122-5p
Number of subjects: 0
Study 33407676 — intervention group
Group type: EXPERIMENTAL
Intervention: Sebelipase alfa enzyme replacement therapy (once-weekly intravenous infusions)
Number of subjects: 19
Study 33407676 — intervention group
Group type: EXPERIMENTAL
Intervention: Sebelipase alfa enzyme replacement therapy
Number of subjects: 19
Study 33407685 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod treatment for 12 months
Number of subjects: 6
Study 33407685 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF BDNF levels
Number of subjects: 6
Study 33407727 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month exergame intervention (simultaneous moderate-intensity aerobic cycling and cognitive training)
Number of subjects: 96
Study 33407727 — intervention group
Group type: COMPARATOR
Intervention: Cycling only
Number of subjects: 96
Study 33407727 — intervention group
Group type: COMPARATOR
Intervention: Attention control (stretching)
Number of subjects: 96
Study 33407782 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week progressive exercise intervention consisting of supervised exercise sessions delivered three times per week by a trained exercise specialist.
Number of subjects: 0
Study 33407794 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 × 10^6 autologous adipose-derived stromal cells (ADSCs)
Number of subjects: 9
Study 33407794 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 × 10^6 autologous adipose-derived stromal cells (ADSCs)
Number of subjects: 9
Study 33407910 — intervention group
Group type: EXPERIMENTAL
Intervention: iACT (app-assisted acceptance and commitment therapy)
Number of subjects: 12
Study 33407923 — intervention group
Group type: EXPERIMENTAL
Intervention: In-bed cycling (20 minutes, 5 days/week)
Number of subjects: 23
Study 33407923 — intervention group
Group type: EXPERIMENTAL
Intervention: In-bed cycling
Number of subjects: 23
Study 33407939 — intervention group
Group type: EXPERIMENTAL
Intervention: Precision Family Spirit
Number of subjects: 60
Study 33407939 — intervention group
Group type: COMPARATOR
Intervention: Standard Family Spirit
Number of subjects: 60
Study 33407947 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component intervention (12-weekly sessions on education, physical activity, stress management, coping skills training) followed by 3 months of continued support and 6 months of skill maintenance
Number of subjects: 80
Study 33407947 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 80
Study 33408185 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin C (MMC)
Number of subjects: 0
Study 33408198 — intervention group
Group type: EXPERIMENTAL
Intervention: Health status measured with the EuroQol-5-dimensions-3-levels (EQ-5D) and EuroQol Visual Analogue Scale at 1 week, 1, 3, 6, 12 and 24 months after injury.
Number of subjects: 4883
Study 33408198 — intervention group
Group type: EXPERIMENTAL
Intervention: Health status dimensions including mobility, pain/discomfort, and usual activities.
Number of subjects: 4883
Study 33408198 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-injury health status, frailty, and length of stay at the hospital.
Number of subjects: 4883
Study 33408198 — intervention group
Group type: EXPERIMENTAL
Intervention: Spine injury, lower and upper extremity injury.
Number of subjects: 4883
Study 33408198 — intervention group
Group type: EXPERIMENTAL
Intervention: Traumatic brain injury.
Number of subjects: 4883
Study 33408199 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal pain assessment using sensor-fusion and machine-learning algorithms (facial electromyography, ECG, electrodermal activity, changes in oxygen saturations, skin perfusion, electroencephalography)
Number of subjects: 60
Study 33408512 — intervention group
Group type: EXPERIMENTAL
Intervention: GMB 120 mg
Number of subjects: 459
Study 33408512 — intervention group
Group type: EXPERIMENTAL
Intervention: GMB 240 mg
Number of subjects: 459
Study 33408512 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 459
Study 33408684 — intervention group
Group type: EXPERIMENTAL
Intervention: Theta-Burst Stimulation
Number of subjects: 0
Study 33408684 — intervention group
Group type: COMPARATOR
Intervention: Sham-Controlled
Number of subjects: 0
Study 33408796 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained Acoustic Medicine (SAM) combined with 1% diclofenac ultrasound gel patch
Number of subjects: 32
Study 33408874 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity resistance exercise training (HIT-RT)
Number of subjects: 43
Study 33408874 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 43
Study 33408874 — intervention group
Group type: EXPERIMENTAL
Intervention: HIT-RT
Number of subjects: 43
Study 33409259 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteroadsorbent Polymethylsiloxane Polyhydrate
Number of subjects: 0
Study 33409259 — intervention group
Group type: COMPARATOR
Intervention: Probiotic
Number of subjects: 0
Study 33409402 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychometric Hepatic Encephalopathy Score (PHES)
Number of subjects: 54
Study 33409459 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg/day
Number of subjects: 98
Study 33409459 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 33409860 — intervention group
Group type: EXPERIMENTAL
Intervention: Change of ultrasonographic (US) air bronchogram score (USINCHILD score) after 48 hours
Number of subjects: 36
Study 33409867 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous IgPro20 at 25 mL, Volume Cohort
Number of subjects: 33
Study 33409867 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous IgPro20 at 40 mL, Volume Cohort
Number of subjects: 33
Study 33409867 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous IgPro20 at 25 mL/h, Flow Rate Cohort
Number of subjects: 33
Study 33409867 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous IgPro20 at 75 mL/h, Flow Rate Cohort
Number of subjects: 33
Study 33409867 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous IgPro20 at 100 mL/h, Flow Rate Cohort
Number of subjects: 33
Study 33409867 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous IgPro20, Volume Cohort
Number of subjects: 33
Study 33409867 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous IgPro20, Flow Rate Cohort
Number of subjects: 33
Study 33409867 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous IgPro20
Number of subjects: 33
Study 33409898 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorinostat 200 mg orally twice daily continuously until progression or unacceptable toxicity
Number of subjects: 14
Study 33409898 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorinostat
Number of subjects: 14
Study 33410093 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic insulin aspart 30/70 (BIAsp 30) in an insulin pen (FlexPen)
Number of subjects: 505
Study 33410093 — intervention group
Group type: COMPARATOR
Intervention: Biphasic insulin aspart 30/70 (BIAsp 30)
Number of subjects: 505
Study 33410109 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ) and Indapamide combination
Number of subjects: 0
Study 33410109 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ) alone
Number of subjects: 0
Study 33410109 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide alone
Number of subjects: 0
Study 33410109 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide
Number of subjects: 0
Study 33410356 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral femoral lengthening
Number of subjects: 10
Study 33410485 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular steroid injection
Number of subjects: 18120
Study 33410523 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag (EPAG) plus standard immunosuppressive therapy (IST)
Number of subjects: 40
Study 33410523 — intervention group
Group type: COMPARATOR
Intervention: Historical IST cohort (n = 87)
Number of subjects: 40
Study 33410523 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag (EPAG) plus standard IST
Number of subjects: 40
Study 33410760 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth DRIVE program
Number of subjects: 84
Study 33410760 — intervention group
Group type: COMPARATOR
Intervention: SafeCare provider feedback
Number of subjects: 84
Study 33410959 — intervention group
Group type: EXPERIMENTAL
Intervention: GTV1 before RCT (mean 154.4 ml, 95% CI: 1.5-877)
Number of subjects: 347
Study 33410959 — intervention group
Group type: EXPERIMENTAL
Intervention: GTV2 at 40-50 Gy (mean 106.2 ml, 95% CI: 0.5-589.5)
Number of subjects: 347
Study 33410959 — intervention group
Group type: EXPERIMENTAL
Intervention: Absolute decrease from GTV1 to GTV2
Number of subjects: 347
Study 33410959 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative change between GTV1 and GTV2
Number of subjects: 347
Study 33410970 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol anesthesia
Number of subjects: 167
Study 33410985 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketone monoester supplement with a regular carbohydrate-containing diet
Number of subjects: 0
Study 33410985 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketogenic diet
Number of subjects: 0
Study 33410985 — intervention group
Group type: COMPARATOR
Intervention: Control group (regular diet without ketone monoester)
Number of subjects: 0
Study 33411095 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative microcirculatory dysfunction identified by iontophoresis of acetylcholine (ACh)
Number of subjects: 60
Study 33411231 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 2579
Study 33411364 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet adherence (MD score)
Number of subjects: 410
Study 33411364 — intervention group
Group type: COMPARATOR
Intervention: High MD scores without statin use
Number of subjects: 410
Study 33411452 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral biopsychosocial explanation ('mind and body work together')
Number of subjects: 308
Study 33411452 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomedical explanations ('excitable nerves', 'over-excited state')
Number of subjects: 308
Study 33411452 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive framed explanations ('mind is a great storyteller')
Number of subjects: 308
Study 33411452 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive bias regarding pain
Number of subjects: 308
Study 33411452 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional reactions to explanations
Number of subjects: 308
Study 33411456 — intervention group
Group type: EXPERIMENTAL
Intervention: Same-Day Discharge (SDD) protocol
Number of subjects: 47
Study 33411456 — intervention group
Group type: COMPARATOR
Intervention: Routine care (discharge ≥ postoperative day 1)
Number of subjects: 47
Study 33411732 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation (DBS) candidates with motor fluctuations
Number of subjects: 333
Study 33411755 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary (TIMP-2) x (IGFBP7) levels at POD1 in patients with po-AKI
Number of subjects: 93
Study 33411755 — intervention group
Group type: COMPARATOR
Intervention: Urinary (TIMP-2) x (IGFBP7) levels at POD1 in patients without po-AKI
Number of subjects: 93
Study 33411755 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary (TIMP-2) x (IGFBP7) levels at PO
Number of subjects: 93
Study 33411755 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary (TIMP-2) x (IGFBP7) levels at POD1 in KDIGO stage 3 po-AKI patients
Number of subjects: 93
Study 33411755 — intervention group
Group type: COMPARATOR
Intervention: Previously proposed cutoff levels (0.3)
Number of subjects: 93
Study 33411755 — intervention group
Group type: COMPARATOR
Intervention: Previously proposed cutoff levels (2)
Number of subjects: 93